X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Researchers Develop Revolutionary Treatment In Bone Cancer

Content Team by Content Team
10th March 2023
in News, Research & Development

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Researchers from the University of East Anglia- UEA have come up with a new non-invasive treatment for bone cancer that happens to be effective against all primary forms of the disease. Notably, the current bone cancer treatment remains invasive and painful and often involves limb amputation as well as chemotherapy that is outdated. Even after procedures, the five-year survival rate for bone cancer just happens to be 42%. This is mainly due to the fact that bone cancer spreads quickly to the lungs.

Bone cancer, which tends to affect predominantly children, begins in the bones, unlike other types of cancer that might spread through the bones. As per UEA research, CADD522, the new drug, can go on to block the gene associated with the spread of bone cancer. This was evident when a mouse was implanted with human bone cancer. In most of the cases, the bone cancer causes largely remain unknown. That said, previous exposure to radiation when it comes to radiotherapy increases the disease level. It is well to be noted that the Li-Fraumeni syndrome, as well as Paget’s disease of the bones, can go on to cause the disease. However, both conditions happen to be rare.

Apparently, the study, which is titled YBX1- interacting small RNAs as well as RUNX2 can be blocked in primary bone cancer by way of using CADD522, the researchers happen to be of the opinion that CADD522 can go on to elevate the survival rates by 50% and also eradicate any sort of surgery as well as chemotherapy that is required. The best part is that the drug has no side effects that are usually associated with chemotherapy, like tiredness, hair loss, or sickness.

As per Dr. Darren Green, the lead researcher from UEA’s Norwich Medical School, primary bone cancer begins in the bones and is the third largest form of childhood cancer, right after brain and kidney. There are around 52000 new cases reported annually across the world. He added that the fact that it spreads rapidly to other body parts is the most challenging aspect of this kind of cancer. Once this cancer spreads, it becomes very cumbersome to treat it with the intent of curing it.

What’s next on the cards is that CADD522 will go through a formal toxicology assessment. The research done after this will stack all the data and approach the MHRA formally for clinical trials so as to begin their treatment of bone cancer.

Previous Post

Singapore Precision Drugs To Excel By Next-Gen Proteomics

Next Post

Default Eligibility Results In Better Clinical Trial Nods

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

Default Eligibility Results In Better Clinical Trial Nods

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In